Nándor Prontvai

Mr. Nándor Prontvai

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2025 in Applied Sciences
Verified
Journal Article
Open access
PDF file
SKSzilvia Kóra
Szilvia Kóra
GWGyörgy Wersényi
György Wersényi
PPPéter Prukner
Péter Prukner
IDIstván Drotár
István Drotár
NPNándor Prontvai
Nándor Prontvai
József TollárJózsef Tollár
József Tollár
Parkinson’s disease (PD) is a progressive movement disorder with no cure. In this randomized controlled study, 100 patients with PD were assigned to four intervention groups (Exergame, Cycling, Agility, and Robot) for 14 weeks. This study evaluates the effectiveness of high-intensity therapy in a randomized clinical trial. Exergaming, cycling, agility, and robot therapies improved motor function, postural stability, and cardiovascular health. Heart rate monitoring and Borg Scale ratings confirmed the safety and adaptability of high-intensity training, with patients sustaining moderate-to-high exertion without adverse effects. Significant improvements were observed in gait speed (+0.30–0.50 m/s), Functional Independence Measure (FIM) (+25–30 points), and Berg Balance Scale scores. Integrating high-intensity, functional movement-based therapies into PD rehabilitation may offer superior motor, gait, and cardiovascular benefits compared to conventional methods.

18 December 2025 in Sensors
Verified
Journal Article
Open access
PDF file
NPNándor Prontvai
Nándor Prontvai
SKSzilvia Kóra
Szilvia Kóra
BTBlanka Törő
Blanka Törő
BKBarbara Kopácsi
Barbara Kopácsi
PKPetra Kós
Petra Kós
József TollárJózsef Tollár
József Tollár
Strokes are one of the leading causes of adult disability. There are a wide range of therapies available in stroke care for people with stroke, but there can be wide variations in the effectiveness of these therapies, so it is essential to review and compare them from time to time. In our study, we measured and compared the effectiveness of three high-intensity therapies: an agility training program without technological tools, a virtual reality exergaming training program with a low-cost device, and a high-cost robotic training program using augmented and virtual reality. All three therapies helped to improve the patients’ functional abilities, balance, and gait. On average, endurance increased by 104–177%, balance scores by 36–53%, and gait speed by 5–10% depending on the intervention. Robotic therapy and exergaming facilitate greater improvements in walking speed, step length, and balance-related gait metrics. These findings have profound implications for stroke rehabilitation, advocating for the prioritization of robotic and exergaming interventions over conventional functional therapies, like agility training. Given the limited sample size, the results should be interpreted as preliminary, highlighting the need for further studies with larger cohorts.

8 June 2026 in Technologies
Verified
Journal Article
Open access
PDF file
BKBarbara Kopácsi
Barbara Kopácsi
NPNándor Prontvai
Nándor Prontvai
BTBlanka Törő
Blanka Törő
PKPetra Kós
Petra Kós
DKDóra Kozma
Dóra Kozma
József TollárJózsef Tollár
József Tollár
People living with neurological disorders frequently experience gait impairments that substantially reduce mobility, independence, and quality of life. This pilot study aimed to evaluate the feasibility, safety, and preliminary functional outcomes of integrating the EksoNR robotic exoskeleton (Ekso Bionics, San Rafael, CA, USA) into outpatient neurorehabilitation practice in individuals with chronic neurological impairments. Over an eight-month period, five participants with heterogeneous neurological conditions (two spinal cord injuries, one cerebellar ataxia, one ischemic stroke, and one spastic paraparesis) completed a four-week robotic gait training program consisting of 15 intervention sessions. Functional outcomes were assessed before and after the intervention using standardized clinical tests. Cardiovascular endurance was evaluated using the 6-Minute Walk Test (6MWT), while physical and psychological well-being were assessed with the Functional Independence Measure (FIM) and the Barthel Index, in addition to the WHO Quality of Life (WHOQOL) and EQ-5D-5L questionnaires. Mobility and balance were evaluated using the Timed Up and Go (TUG), Berg Balance Scale (BBS), Tinetti Performance-Oriented Mobility Assessment (POMA), and Walking Index for Spinal Cord Injury II (WISCI II), where applicable. In addition, device-recorded gait parameters, including step count, step length, walking distance, and walking duration, were analyzed. Significant improvements were observed in several device-derived gait parameters, including the number of steps performed with the exoskeleton (p < 0.001), step length (p = 0.003), walking distance (p = 0.002), and walking duration (p < 0.05). Significant improvements were also identified in balance performance (BBS: p = 0.006; Tinetti POMA: p = 0.001), cardiovascular endurance (6MWT: p = 0.017), and EQ-5D-5L scores (p = 0.038). Functional independence measures (FIM and BI), TUG performance, and WHOQOL domains did not demonstrate statistically significant changes. No serious adverse events or device-related injuries occurred during the intervention period. Due to the small and clinically heterogeneous sample, these findings should be interpreted as preliminary exploratory results. Nevertheless, the study supports the feasibility and potential clinical utility of EksoNR-assisted gait rehabilitation and provides a basis for larger controlled investigations.

13 November 2026 in Bioengineering
Verified
Journal Article
Open access
PDF file
BTBlanka Törő
Blanka Törő
SKSzilvia Kóra
Szilvia Kóra
PKPetra Kós
Petra Kós
NPNándor Prontvai
Nándor Prontvai
VAViktória Alföldi
Viktória Alföldi
József TollárJózsef Tollár
József Tollár
Background: Instrumented human-movement assessment can be integrated with neurological examination and clinical scales to objectify functional deficits and quantify rehabilitation-related change. We evaluated a diagnostic-integration pathway in which TecnoBody ProKin posturography and Xsens MVN Awinda gait analysis were embedded in routine hospital neurorehabilitation as objective functional-diagnostic and outcome-monitoring tools. Methods: This manuscript reports a secondary exploratory longitudinal analysis of prospectively acquired routine-care measurements. The publication dataset comprised 151 participants with baseline posturography (stroke, n = 90; Parkinson’s disease, n = 38; multiple sclerosis [MS], n = 23); baseline gait data were available for 107. Diagnosis-specific Gaussian random-intercept models were fitted by restricted maximum likelihood with categorical time, and global time effects and PRE-to-POST contrasts were controlled using Benjamini–Hochberg False Discovery Rate (FDR) correction. Results: In stroke, dynamic open-eye Total Stability Index (TSI) showed an FDR-significant global time effect (Wald χ2(4) = 18.07, p = 0.00120, q = 0.00717), with lower model-estimated TSI at POST 2 (−1.46°, q = 0.0121; standardized effect = −0.50) and POST 3 (−1.92°, q = 0.0121; standardized effect = −0.65). Stroke cadence showed a global longitudinal signal in the full model (q = 0.0443); however, this finding did not remain FDR-significant in a sensitivity analysis excluding the sparsely populated POST 4 milestone (q = 0.139) and was therefore interpreted as exploratory. In Parkinson’s disease, the POST 1 TSI contrast was supportive only because the endpoint-level global test did not survive FDR correction. MS follow-up was insufficient for strong longitudinal inference, particularly for gait, and is interpreted primarily as a feasibility/data-availability finding. Conclusions: Diagnostic integration of ProKin and Xsens into routine neurorehabilitation was feasible and generated objective patient-specific trajectories for balance and gait outcome monitoring. The measurements can objectify rehabilitation-related functional change, but the uncontrolled design does not establish causal treatment efficacy, and clinically meaningful individual-change thresholds remain to be validated.